Targeting Nectin-4 in Bladder Cancer

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-nb2017-095
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors

Unknown

Publisher

American Association for Cancer Research (AACR)

Related search

Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models

Cancer Research
Cancer ResearchOncology
2016English

A Place for Precision Medicine in Bladder Cancer: Targeting the FGFRs

Future Oncology
MedicineCancer ResearchOncology
2016English

Isorhapontigenin (ISO) Inhibits Invasive Bladder Cancer Formation in Vivo and Human Bladder Cancer Invasion in Vitro by Targeting STAT1/FOXO1 Axis

Cancer Prevention Research
MedicineCancer ResearchOncology
2016English

Targeting Claudin-4 Enhances CDDP-chemosensitivity in Gastric Cancer

Oncotarget
Oncology
2019English

Nectin-4 Expression Is an Independent Prognostic Biomarker and Associated With Better Survival in Triple-Negative Breast Cancer

Frontiers in Medicine
Medicine
2019English

MicroRNA‑154 Functions as a Tumor Suppressor in Bladder Cancer by Directly Targeting ATG7

Oncology Reports
MedicineCancer ResearchOncology
2018English

Lentivirus-Mediated shRNA Targeting MUTYH Inhibits Malignant Phenotypes of Bladder Cancer SW780 Cells

OncoTargets and Therapy
OncologyPharmacology
2018English

microRNA-125b Inhibits Cell Migration and Invasion by Targeting Matrix Metallopeptidase 13 in Bladder Cancer

Oncology Letters
Cancer ResearchOncology
2013English

Bladder Cancer

Nature
Multidisciplinary
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy